JAB-8263

DRUG3 trials

Sponsors

Jacobio Pharmaceuticals Co., Ltd.

Conditions

AMLCRPCESCCMFMalignant TumorNSCLCOvarian CarcinomaRheumatoid Arthritis (RA)

Phase 1

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

CompletedNCT04587479

Jacobio Pharmaceuticals Co., Ltd.Solid Tumors, Adult

Start: 2020-11-23End: 2024-10-31Updated: 2026-01-13

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

RecruitingNCT04686682

Jacobio Pharmaceuticals Co., Ltd.AML, CRPC, ESCC +5

Start: 2021-05-07End: 2028-07-31Target: 152Updated: 2026-01-09

Phase 2

A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis

Not yet recruitingNCT07684157

Jacobio Pharmaceuticals Co., Ltd.Rheumatoid Arthritis (RA)

Start: 2026-07-29End: 2027-12-31Target: 32Updated: 2026-07-06

Related Papers

Preliminary Results of Patients with Myelofibrosis (MF) from a Phase I Trial of Jab-8263, a Potent BET Inhibitor

Blood2024-11-05

Preclinical Evaluation of JAB-2485, a Potent AURKA Inhibitor with High Selectivity and Favorable Pharmacokinetic Properties

ACS Omega2024-05-033 citations